[go: up one dir, main page]

MX2021006111A - Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide. - Google Patents

Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.

Info

Publication number
MX2021006111A
MX2021006111A MX2021006111A MX2021006111A MX2021006111A MX 2021006111 A MX2021006111 A MX 2021006111A MX 2021006111 A MX2021006111 A MX 2021006111A MX 2021006111 A MX2021006111 A MX 2021006111A MX 2021006111 A MX2021006111 A MX 2021006111A
Authority
MX
Mexico
Prior art keywords
rheumatoid arthritis
treatment
csf antibodies
mor103
dosages
Prior art date
Application number
MX2021006111A
Other languages
English (en)
Inventor
Stefan Steidl
Stefan Haertle
Stephane Leclair
Amgad Shebl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2021006111A publication Critical patent/MX2021006111A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos anti-GM-CSF para usarse en el tratamiento de artritis reumatoide. Los anticuerpos anti-GM-CSF, en particular MOR103, se administran a los pacientes que padezcan de artritis reumatoide en dosificaciones que sean benéficas en una situación clínica.
MX2021006111A 2012-09-20 2015-03-20 Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide. MX2021006111A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21

Publications (1)

Publication Number Publication Date
MX2021006111A true MX2021006111A (es) 2021-07-07

Family

ID=46963526

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003644A MX382937B (es) 2012-09-20 2013-09-19 Composición farmacéutica que comprende unanticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.
MX2021006111A MX2021006111A (es) 2012-09-20 2015-03-20 Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015003644A MX382937B (es) 2012-09-20 2013-09-19 Composición farmacéutica que comprende unanticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.

Country Status (22)

Country Link
US (4) US20150246969A1 (es)
EP (3) EP3916013A1 (es)
JP (4) JP2015533806A (es)
KR (4) KR20230041086A (es)
CN (2) CN109999195A (es)
AU (2) AU2013320261A1 (es)
BR (1) BR112015006189B1 (es)
CL (2) CL2015000696A1 (es)
CR (1) CR20150153A (es)
DO (1) DOP2015000070A (es)
EA (1) EA031489B1 (es)
HK (1) HK1208231A1 (es)
IL (1) IL237554B (es)
IN (1) IN2015KN00657A (es)
MA (1) MA37946B1 (es)
MX (2) MX382937B (es)
MY (1) MY175388A (es)
PE (1) PE20151079A1 (es)
PH (1) PH12015500591A1 (es)
SG (2) SG11201501595YA (es)
UA (1) UA117228C2 (es)
WO (1) WO2014044768A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY175388A (en) * 2012-09-20 2020-06-23 Morphosys Ag Treatment for rheumatoid arthritis
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) * 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
WO2015028657A1 (en) * 2013-08-30 2015-03-05 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
WO2015138638A1 (en) * 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
ES2974895T3 (es) 2014-05-07 2024-07-02 Takeda Pharmaceuticals Co Formulación líquida que comprende un compuesto neutralizante de GM-CSF
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
AU2016371021B2 (en) 2015-12-17 2020-04-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
JP7281795B2 (ja) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
KR101953706B1 (ko) * 2016-09-19 2019-03-05 아이-맵 항-gm-csf 항체 및 이것의 사용
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2025218746A1 (en) * 2024-04-17 2025-10-23 Sinomab Bioscience Limited Methods of treating rheumatoid arthritis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1998014476A1 (en) 1996-10-04 1998-04-09 Amgen Inc. Pharmaceutical compositions containing an mpl ligand
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
PL3620171T3 (pl) * 2005-05-18 2022-08-08 Morphosys Ag Przeciwciała anty-gm-csf i ich zastosowania
US7790679B2 (en) 2005-08-05 2010-09-07 Amgen Inc. Pharmaceutical formulations
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US8093360B2 (en) * 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
CA2682170A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Antibodies with decreased deamidation profiles
WO2008122007A1 (en) * 2007-04-02 2008-10-09 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
DE602008004235D1 (de) 2007-04-05 2011-02-10 Sandoz Ag Stabile wässrige g-csf-formulierungen
US20090004189A1 (en) * 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PT2215119E (pt) * 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CA2747206C (en) 2008-12-22 2018-04-24 The University Of Melbourne Pain treatment
PL2376121T5 (pl) 2008-12-22 2021-09-27 The University Of Melbourne Leczenie zapalenia kości i stawów
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
AU2010244525B2 (en) * 2009-05-05 2013-03-28 Morphosys Ag Treatment for multiple sclerosis
DK2341061T3 (da) 2009-12-31 2013-11-04 Arven Ilac Sanayi Ve Ticaret As Ny fremgangsmåde til fremstilling af G-CSF (granulocytkoloni-stimulerende faktor)
CN105521491B (zh) * 2010-03-01 2020-03-24 西托戴恩有限公司 浓缩蛋白制剂及其用途
JP2014520784A (ja) 2011-07-06 2014-08-25 モルフォシス・アー・ゲー 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用
MY175388A (en) * 2012-09-20 2020-06-23 Morphosys Ag Treatment for rheumatoid arthritis

Also Published As

Publication number Publication date
AU2016250388A1 (en) 2016-11-17
KR20230041086A (ko) 2023-03-23
WO2014044768A1 (en) 2014-03-27
CA2884124A1 (en) 2014-03-27
JP2018138551A (ja) 2018-09-06
EP2897977A1 (en) 2015-07-29
IL237554A0 (en) 2015-04-30
CN104995210A (zh) 2015-10-21
BR112015006189B1 (pt) 2022-04-05
US20210130451A1 (en) 2021-05-06
AU2013320261A1 (en) 2015-04-09
EP3916013A1 (en) 2021-12-01
PH12015500591B1 (en) 2015-05-11
BR112015006189A2 (pt) 2019-11-26
KR20150056846A (ko) 2015-05-27
US10913792B2 (en) 2021-02-09
KR20220028177A (ko) 2022-03-08
JP2022169709A (ja) 2022-11-09
CL2015000696A1 (es) 2015-10-23
CR20150153A (es) 2015-09-14
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
MA37946B1 (fr) 2018-09-28
HK1208231A1 (en) 2016-02-26
EA201590359A1 (ru) 2015-08-31
DOP2015000070A (es) 2015-08-16
MX382937B (es) 2025-03-13
SG10201803778PA (en) 2018-06-28
JP2015533806A (ja) 2015-11-26
PH12015500591A1 (en) 2015-05-11
IL237554B (en) 2019-12-31
JP2024156992A (ja) 2024-11-06
US20150246969A1 (en) 2015-09-03
EP3345923A1 (en) 2018-07-11
CL2018000933A1 (es) 2018-07-20
KR20240091288A (ko) 2024-06-21
MA37946A1 (fr) 2018-01-31
CN109999195A (zh) 2019-07-12
PE20151079A1 (es) 2015-08-07
US20180230208A1 (en) 2018-08-16
US20240417455A1 (en) 2024-12-19
EA031489B1 (ru) 2019-01-31
MX2015003644A (es) 2015-09-25
UA117228C2 (uk) 2018-07-10
IN2015KN00657A (es) 2015-07-17
AU2016250388B2 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
MX2021006111A (es) Composicion farmaceutica que comprende un anticuerpo anti-gm-csf para usarse en el tratamiento de artritis reumatoide.
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
MX342810B (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
NZ730763A (en) Methods of treating a tauopathy
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
IL235672A0 (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
UA113403C2 (xx) Спосіб підвищення ефективності folr1 терапії раку
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
SMT201700387T1 (it) Terapia di combinazione implicante anticorpi contro claudina 18.2 per il trattamento del cancro
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions